Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer (NCT06686771)
Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression In Patients With Metastatic Non-Small-Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
- SBRT (RADIATION)
- First or second-line standard of care therapy (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (75 Sites)
Showing the first 25 of 75 sites.
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- City of Hope Comprehensive Cancer Center — Duarte, California
- City of Hope at Irvine Lennar — Irvine, California
- Saint Mary's Hospital and Regional Medical Center — Grand Junction, Colorado
- CTCA at Southeastern Regional Medical Center — Newnan, Georgia
- Saint Luke's Cancer Institute - Boise — Boise, Idaho
- Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
- Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
- Saint Luke's Cancer Institute - Nampa — Nampa, Idaho
- Alton Memorial Hospital — Alton, Illinois
- Northwestern University — Chicago, Illinois
- Decatur Memorial Hospital — Decatur, Illinois
- Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois
- Crossroads Cancer Center — Effingham, Illinois
- Northwestern Medicine Cancer Center Delnor — Geneva, Illinois
- Northwestern Medicine Glenview Outpatient Center — Glenview, Illinois
- Northwestern Medicine Grayslake Outpatient Center — Grayslake, Illinois
- Northwestern Medicine Lake Forest Hospital — Lake Forest, Illinois
- HSHS Saint Elizabeth's Hospital — O'Fallon, Illinois
- Northwestern Medicine Oak Brook — Oak Brook, Illinois
- Northwestern Medicine Orland Park — Orland Park, Illinois
- Memorial Hospital East — Shiloh, Illinois
- Northwestern Medicine Cancer Center Warrenville — Warrenville, Illinois
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- Mercy Hospital — Cedar Rapids, Iowa
📞 Contact the Study Coordinator
Phone: (613) 533-6430
Email: p-ogaudreau@ctg.queensu.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-small Cell Lung Cancer
- Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations — Birmingham, Alabama
- Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — La Jolla, California
- PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer — Houston, Texas
- Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer — Renton, Washington
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer — Boston, Massachusetts
- Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Chandler, Arizona
Explore by condition: All Non-small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.